Checkmate Pharmaceuticals, Inc. announced the addition of Joy Yan, M.D., Ph.D. to its Board of Directors (“Board”). Dr. Yan currently serves as Chief Medical Officer at Ambrx Biopharma Inc., a biopharmaceutical company with an expanded genetic code technology platform, where she led the pipeline strategy and quickly advanced three antibody drug conjugate development programs. Previously, at Bristol Myers Squibb, she led the successful development of multiple oncology products from strategic planning through global submissions and approvals, including BMS’ first FDA Pilot Programs (RTOR, Project ORBIS, AAid) for nivolumab and ipilimumab. She also has broad clinical development experience from working at Janssen Pharmaceutical and Bayer AG, where she led Phase I, II and III studies exploring a variety of MOAs and evaluated NMEs (daratumumab, radium-223, anti-IL3R, Bi-specifics, ADCs, TKIs) across multiple tumor types. Dr. Yan completed her Ph.D. in Biochemistry & Molecular Biology at Johns Hopkins University. She received her M.D. from China Medical University and completed her residency and clinical fellowship at the University of Washington.